Prediction of Therapeutic Efficacy of Gabapentin by Hull Airway Reflux Questionnaire in Chronic Refractory Cough

Zhang, Mengru; Chen, Qiang; Dong, Ruiqi; Ai, Zisheng; Xu, Xianghuai; Qiu, Zhongmin

doi:10.21203/rs.3.rs-40955/v1

Cited by 4 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HARQ was specifically developed to codify the symptom complex in chronic cough, assessing diagnostic components of the history [94]. It has since been used to assess patients with unexplained respiratory symptoms [18] and to support the diagnosis of chronic cough in patients participating in clinical trials [95,96]. For, example, in COUGH-1 and COUGH-2, the HARQ score was elevated in 95% of over 2000 rigorously identified patients with chronic cough [4].…”

Section: Diagnosismentioning

confidence: 99%

“…A range of treatments is currently recommended for managing chronic cough (table 2 [101][102][103][104][105][106][107][108][109][110][111]). The drugs with the strongest level of recommendation in European Respiratory Society (ERS) guidelines are neuromodulators including low-dose morphine [78], gabapentin [96,80], pregabalin [81] and amitriptyline [112]. Identifying the correct treatment can be challenging, since it is often not clear which phenotype of cough should be treated and patients can vary greatly in responsiveness [2].…”

Section: Current Treatments For Chronic Coughmentioning

confidence: 99%

“…High sensitivity and specificity [94]. Used in clinical trials [95,96]. Translations are available in over 20 languages, including Mandarin Chinese [97] and Swedish [98].…”

Section: Harq [94] 14 Items Covering Major Components Of Chronic Coughmentioning

confidence: 99%

See 2 more Smart Citations

Chronic cough: new insights and future prospects

et al. 2021

View full text Add to dashboard Cite

Chronic cough is defined in adults as a cough that lasts for ≥8 weeks. When it proves intractable to standard-of-care treatment, it can be referred to as refractory chronic cough (RCC). Chronic cough is now understood to be a condition of neural dysregulation. Chronic cough and RCC result in a serious, often unrecognized, disease burden, which forms the focus of the current review.The estimated global prevalence of chronic cough is 2–18%. Patients with chronic cough and RCC report many physical and psychological effects, which impair their quality of life. Chronic cough also has a significant economic burden for the patient and healthcare systems. RCC diagnosis and treatment are often delayed for many years as potential treatable triggers must be excluded first and a stepwise empirical therapeutic regimen is recommended.Evidence supporting most currently recommended treatments is limited. Many treatments do not address the underlying pathology, are used off-label, have limited efficacy and produce significant side-effects. There is therefore a significant unmet need for alternative therapies for RCC that target the underlying disease mechanisms. Early clinical data suggest that antagonists of the purinergic P2X3 receptor, an important mediator of RCC, are promising, though more evidence is needed.

show abstract

Section: Diagnosismentioning

confidence: 99%

Section: Current Treatments For Chronic Coughmentioning

confidence: 99%

See 1 more Smart Citation

Chronic cough: new insights and future prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Moreover, Zhang et al show that the HARQ has moderate value in predicting the treatment response of gabapentin, while C2 and C5 values from the capsaicin cough test are useless in this regard. 90 Gabapentin has been shown to reduce severity of cough, providing further evidence of central sensitization. 91 The predictive value of the HARQ on the efficacy of gabapentin indicates that certain items in the HARQ (such as laryngeal itching or obstruction, cough when eating, and morning cough) indirectly reflect central cough hypersensitivity, 90 further confirming that the HARQ can be used to indirectly evaluate cough sensitivity.…”

Section: Evaluation Methods For Cough Sensitivitymentioning

confidence: 99%

“… 90 Gabapentin has been shown to reduce severity of cough, providing further evidence of central sensitization. 91 The predictive value of the HARQ on the efficacy of gabapentin indicates that certain items in the HARQ (such as laryngeal itching or obstruction, cough when eating, and morning cough) indirectly reflect central cough hypersensitivity, 90 further confirming that the HARQ can be used to indirectly evaluate cough sensitivity. The HARQ provides a subjective evaluation of cough sensitivity.…”

Section: Evaluation Methods For Cough Sensitivitymentioning

confidence: 99%

Evaluation methods and influencing factors of cough sensitivity

Mei

Ran

et al. 2022

Ther Adv Respir Dis

Self Cite

View full text Add to dashboard Cite

Increased cough sensitivity is an important mechanism of chronic cough, and the evaluation of cough sensitivity helps understand the mechanism of cough and explore better methods to reduce cough. Evaluation methods may be direct or indirect. Direct methods include mechanical stimulation and chemical stimulation, and indirect methods include laryngeal reflex test, questionnaires, and brain functional magnetic resonance imaging (fMRI). Chemical stimulation is the most common method, while the capsaicin cough challenge test is proven and widely used. In this article, we will compare evaluation methods and explore influencing factors of cough sensitivity.

show abstract

Qualitative assessment of sensations and triggers in chronic cough

Hirons,

Rhatigan,

Kesavan

et al. 2023

ERJ Open Res

View full text Add to dashboard Cite

Extract This qualitative study involved single, one-on-one, semi-structured interviews with patients recruited from a specialist cough centre. All participants had RCC, defined according to European Respiratory Society guidelines [4], with no recent respiratory infection (within 6 weeks). Clinical assessment deemed that, despite current management of treatable traits or use of neuromodulators, chronic cough was not suppressed. Participants gave informed consent, and the study was approved by East London and the City Research Ethics Committee (reference 10/H0703/6). A single interviewer (B. Hirons) with experience in qualitative interview methodology conducted interviews using a standardised, semi-structured guide, developed by a chronic cough multidisciplinary team. Through concept elicitation, open-ended questions were utilised to discuss and assess a wide range of personal cough triggers and sensations, followed by prompting for commonly known ones. Each interview was coded for qualitative content analysis using methodology described by W illis [12]. A coding dictionary of key concepts was created, then tested by coding subsequent transcripts. One researcher coded all transcripts using the constant comparative method. This iterative coding approach involved moving back and forth between consecutive transcripts and incorporating new codes that emerged during the process [13]. Potential themes and subthemes were inputted into a framework matrix to aid recognition of trends and selection of extracts to illustrate participant responses [14]. Interviews ceased at concept saturation, pre-defined as no new concepts elicited for two consecutive interviews [15]. Saturation occurred after the eighth interview.

show abstract

Prediction of Therapeutic Efficacy of Gabapentin by Hull Airway Reflux Questionnaire in Chronic Refractory Cough

Cited by 4 publications

References 30 publications

Chronic cough: new insights and future prospects

Chronic cough: new insights and future prospects

Evaluation methods and influencing factors of cough sensitivity

Qualitative assessment of sensations and triggers in chronic cough

Contact Info

Product

Resources

About